Iridex Receives CE Mark for Transilluminated Probe
The leading-edge G-Probe Illuminate™ glaucoma device with built-in transillumination now available in Europe
MOUNTAIN VIEW, Calif., March 20, 2018 (GLOBE NEWSWIRE) -- IRIDEX Corporation (Nasdaq:IRIX) is pleased to announce the availability of the G-Probe Illuminate™ device in Europe. The probe, now with CE mark, offers combined transillumination and laser fiber for targeted transscleral cyclophotocoagulation (CPC). The G-Probe Illuminate received FDA clearance and was launched in early 2017. It is the third member of the family of probes powered by the CYCLO G6™ Glaucoma Laser System. This delivery device features built-in transillumination, which optimizes placement of the probe and therapeutic outcomes.
Studies have shown the ciliary body, the target tissue for a CPC treatment, naturally varies in location between patients, and cases of abnormal ocular size, high myopia and post-corneal transplants generate even more challenges. The G-Probe Illuminate may improve the ability of physicians to locate the ciliary body and deliver the laser treatment in a more targeted manner.
“The G-Probe Illuminate is a highly-anticipated product for me. This new design will help me deliver a targeted cyclophotocoagulation treatment with increased visualization of the ciliary body and surrounding working areas”, says Marc Töteberg-Harms, MD, FEBO. “G-Probe Illuminate allows me to treat my patients with precise accuracy to the desired tissue, especially in patients with abnormal anatomy.”
The G-Probe Illuminate may be utilized in the operating room or as an outpatient, office-based procedure providing a versatile option for treating glaucoma. “The prevalence of glaucoma is only increasing around the world, and IRIDEX is committed to improving and expanding the therapeutic options for both patients and surgeons,” says IRIDEX CEO, William M. Moore.
IRIDEX Corporation is a worldwide leader in developing, manufacturing, and marketing innovative and versatile laser-based medical systems, delivery devices and consumable instrumentation for the ophthalmology market. The Company’s proprietary MicroPulse® technology delivers a differentiated treatment that provides safe, effective, and proven treatment for targeted sight-threatening eye conditions. IRIDEX’s current product line is used for the treatment of glaucoma, diabetic macular edema (DME) and other retinal diseases. IRIDEX products are sold in the United States through a direct sales force and internationally primarily through a network of independent distributors into more than 100 countries. For further information, visit the IRIDEX website at http://www.iridex.com/.
Safe Harbor Statement
This announcement contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Act of 1934, as amended, including those statements concerning the adoption and effect of Company products on its results, the markets in which the Company operates, the Company’s future financial results, and the Company's strategic plans and objectives. These statements are not guarantees of future performance and actual results may differ materially from those described in these forward-looking statements as a result of a number of factors. Please see a detailed description of these and other risks contained in our Annual Report on Form 10-K for the fiscal year ended December 30, 2017, and Quarterly Reports on Form 10-Q for subsequent fiscal quarters, each of which was filed with the Securities and Exchange Commission. Forward-looking statements contained in this announcement are made as of this date and will not be updated.
Pascale Communications, LLC.
Investor Relations Contact:
Lynn Pieper Lewis or Leigh Salvo